Overview
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.
Background
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.
Indication
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and has antipyretic, analgesic and anti-inflammatory properties. It is indicated for short term management of acute pain that requires the calibre of pain management offered by opioids. Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft tissue pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders and headaches among other ailments. Regardless of the etiology of pain, patients should use the lowest possible dose, and avoid using ketorolac for an extended period of time (ideally ≤ 5 days). A benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac use.
Associated Conditions
- Acute Migraine
- Eye Pain
- Inflammation
- Macular Edema, Cystoid
- Ocular Itching
- Pericarditis Acute
- Pseudophakic Cystoid Macular Oedema
- Severe Acute Pain
- Acute, moderate Pain
- Chronic aphakic cystoid macular edema
- Intraoperative miosis
- Postoperative ocular pain
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2016/08/15 | Phase 4 | Completed | Instituto de Oftalmología Fundación Conde de Valenciana | ||
2016/07/12 | Phase 4 | Completed | |||
2016/05/25 | Phase 4 | UNKNOWN | Loredana Ghinea | ||
2016/05/25 | Phase 4 | UNKNOWN | Loredana Ghinea | ||
2016/05/11 | Phase 4 | UNKNOWN | Clinica Santa Maria | ||
2016/05/09 | Phase 4 | Withdrawn | Holy Cross Hospital, Florida | ||
2016/04/27 | Not Applicable | Completed | MDbackline, LLC | ||
2016/04/06 | Phase 4 | Completed | Sun Yat-sen University | ||
2016/03/07 | Not Applicable | Completed | Hospital for Special Surgery, New York | ||
2016/02/25 | Not Applicable | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Camber Pharmaceuticals, Inc. | 31722-306 | INTRAVENOUS, INTRAMUSCULAR | 30 mg in 1 mL | 7/4/2023 | |
Mylan Pharmaceuticals Inc. | 0378-1134 | ORAL | 10 mg in 1 1 | 7/13/2015 | |
Prescription Care LLC | 70486-003 | TOPICAL | 0.09 g in 30 mL | 8/19/2016 | |
Sagent Pharmaceuticals | 25021-701 | INTRAVENOUS, INTRAMUSCULAR | 30 mg in 1 mL | 6/20/2023 | |
A-S Medication Solutions | 50090-4635 | INTRAVENOUS, INTRAMUSCULAR | 30 mg in 1 mL | 6/20/2019 | |
Fresenius Kabi USA, LLC | 63323-161 | INTRAVENOUS, INTRAMUSCULAR | 15 mg in 1 mL | 11/18/2022 | |
Proficient Rx LP | 71205-116 | INTRAVENOUS, INTRAMUSCULAR | 30 mg in 1 mL | 12/1/2018 | |
Direct_Rx | 72189-371 | ORAL | 10 mg in 1 1 | 12/8/2023 | |
A-S Medication Solutions | 50090-5013 | INTRAVENOUS, INTRAMUSCULAR | 30 mg in 1 mL | 1/15/2017 | |
Fresenius Kabi USA, LLC | 63323-162 | INTRAMUSCULAR | 30 mg in 1 mL | 11/18/2022 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |